Literature DB >> 19449018

[Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe].

J Braun1, J Sieper.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19449018     DOI： 10.1007/s00393-009-0464-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  8 in total

1.  [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].

Authors:  J Braun; J Zochling; E Märker-Hermann; G Stucki; H Böhm; M Rudwaleit; H Zeidler; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

Review 2.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

3.  ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

Review 4.  Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists.

Authors:  P I Sidiropoulos; G Hatemi; I-H Song; J Avouac; E Collantes; V Hamuryudan; M Herold; T K Kvien; H Mielants; J M Mendoza; I Olivieri; M Østergaard; L Schachna; J Sieper; D T Boumpas; M Dougados
Journal:  Rheumatology (Oxford)       Date:  2008-03       Impact factor: 7.580

5.  First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

Authors:  J Braun; J Davis; M Dougados; J Sieper; S van der Linden; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

6.  ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version.

Authors:  U Kiltz; D van der Heijde; H Mielants; E Feldtkeller; J Braun
Journal:  Ann Rheum Dis       Date:  2008-10-17       Impact factor: 19.103

7.  [Patient evaluation of the German version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis].

Authors:  U Kiltz; E Feldtkeller; J Braun
Journal:  Z Rheumatol       Date:  2008-12       Impact factor: 1.372

8.  Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists.

Authors:  L Gossec; M Dougados; C Phillips; M Hammoudeh; K de Vlam; K Pavelka; T Pham; J Braun; J Sieper; I Olivieri; D van der Heijde; E Collantes; M Stone; T K Kvien
Journal:  Ann Rheum Dis       Date:  2007-11-29       Impact factor: 19.103
  8 in total
  3 in total

1.  [ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area].

Authors:  U Kiltz; J Sieper; J Braun
Journal:  Z Rheumatol       Date:  2013-02       Impact factor: 1.372

2.  [Advice for patients diagnosed with ankylosing spondylitis: results of a representative patient survey in Germany].

Authors:  E Feldtkeller; L Hammel; C Brenneis; I-H Song; M Rudwaleit
Journal:  Z Rheumatol       Date:  2011-07       Impact factor: 1.372

3.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.